Headshot of Jing Wu

Jing Wu, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 37, Room 1142A
  • Bethesda, MD 20892
  • 240-760-6036
  • 301-480-5124
Neuro-Oncology Branch


Dr. Wu is a clinical neuro-oncologist who leads the Translational Research Program at the Neuro-Oncology Branch (NOB). Her clinical interests revolve around understanding challenges in neuro-oncology care, and developing laboratory and clinical research programs to understand glioma biology and investigate novel therapeutic approaches to improve patient clinical outcomes. Her goal is to observe phenotypes and gaps in knowledge through her clinical practice, in order to address these questions in the laboratory and subsequently develop hypothesis-based clinical trials. 

There are two facets to Dr. Wu’s research. First, she seeks to understand gliomas that exhibit an aggressive phenotype, in order to develop a diagnostic tool to monitor their transformation from low-grade to high-grade disease when they exhibit rapid growth. Her second goal is to test the efficacy of the multi-kinase inhibitor TG02 in clinical trials, in order to understand its effects on high-grade astrocytomas and IDH-mutant gliomas. 

Explore the NOB's Research Programs >

Areas of Expertise

Translational Research
Clinical Trial
IDH-Mutant Gliomas

Information for Patients

Learn about our multidisciplinary approach to patient care, our clinical trials and the highly specialized care teams who lead them.


Selected Key Publications

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.

Jing Wu J, Yuan Y, Priel DAL, Fink D, Peer CJ , Sissung TM, Su Y, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, Grajkowska E, Mentges K, Boris L, Antony R, Garren N, Siegel C, Lollo N, Cordova C, Aboud O, Theeler BJ, Burton EM, Penas-Prado M, Leeper H, Gonzales J, Armstrong TS, Calvo KR, Figg WD, Kuhns DB, Gallin JI, Gilbert MR
Clinical Cancer Research. 27(12): 3298-3306, 2021. [ Journal Article ]

A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.

Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu JM, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR
Neuro-Oncology. 22: 1505–1515 , 2020. [ Journal Article ]

MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.

Su YT, Butler M, Zhang M, Zhang W, Song H, Hwang L, Tran A, Bash RE, Schorzman AN, Pang Y, Yu G, Zamboni WC, Wang X, Frye SV, Miller, Maric C, Terabe M, Gilbert MR, Earp III HS, Wu J
Neuro-Oncology Advances. 2(1): 1–13, 2020. [ Journal Article ]

Novel Targeting of Transcription and Metabolism in Glioblastoma

Su YT, Chen R, Wang HR, Song H, Lappin H, Vasconcelos G, Lita A, Mric D, Celiku O, Li AG, Zhang W, Larion M, Abu-Asab M, Zhuang P,Yang CZ, Gilbert MR, Wu J
Clinical Cancer Research. 24: 1124-1137, 2018. [ Journal Article ]

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair

Lu YX, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon S, MacDonald J, Ewend ME, Gilbert MR, Yang CZ, Wu J
Cancer Research. 77: 1709-1718, 2017. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


Staff Scientist
Peng Lu, Ph.D.
Postdoctoral Fellow (IRTA)
Olga Kim, M.D., Ph.D.
Laboratory Technician
Qi Li
Postbaccalaureate Fellow (IRTA/CRTA)
Zachary Sergi


Close up of a doctor's hands giving a patient's hands pills

New Clinical Trial Tests a Kind of Precision Medicine Treatment for IDH-Mutant Brain Tumors

February 12, 2024

A new trial investigates zotiraciclib as a treatment for people with recurrent gliomas containing an IDH1 or IDH2 mutation to control tumor growth and improve quality of life. Read more >

Blue microscopy image of brain cells under a microscope

FDA grants orphan drug designation to indotecan for the treatment of glioma

November 29, 2023

The FDA granted orphan drug status to LMP400 (indotecan) for use in patients with malignant glioma, a cancer of the brain that begins in glial cells. Read more >

Blue and green microscopy image of brain tumor cells treated with 2 drugs: LMP400 and Niraparib

Powerful Drug Combination Kills Glioblastoma Tumors Containing a Unique Genetic Makeup

September 19, 2023

Researchers conducted preclinical experiments to explore a treatment that damages brain tumors’ DNA and prevents the cells from repairing it. Read more >

Stock image of doctor speaking with a patient as they both smile

Clinical Trial Researches Drug Therapy for CNS Tumors

May 5, 2023

A clinical trial led by Dr. Jing Wu is researching a drug therapy for gliomas that contain mutations in IDH1 and IDH2 genes, which are especially aggressive. Read more >

MRI scan of brain with tumor next to headshot of Jing Wu

Targeting Tumors in the Brain

July 20, 2023

As head of the Translational Research Program, Dr. Jing Wu aims to better understand gliomas and identify potential therapies to treat these tricky brain tumors. Read more >

Headshots of Terri Armstrong, Alvina Acquaye-Mallory, Tracy Ani, and Jing Wu

Neuro-Oncology Branch Members Earn NCI Director’s Awards for Improving Patient Care and Outcomes

April 5, 2023

Dr. Terri Armstrong, Alvina Acquaye-Mallory, and Tracy Ani were recognized for their efforts to make clinical trials more inclusive, while Dr. Jing Wu was recognized for her research on the anticancer drug zotiraciclib. Read more >

Dr. Wu at a computer talking to Dr. Gilbert

Translational Research: Turning Patient Observations and Laboratory Findings into Clinical Trials

September 28, 2021

The Translational Research Program, led by Dr. Jing Wu, leverages laboratory research and patient observations to find new ways to treat brain and spine tumors, as well as improve patient outcomes. Read more >

Dr. Jing Wu and Madison Butler

Women Scientist Appreciation Month

March 1, 2020

In honor of International Women and Girls in Science Day, we celebrated female scientists, physicians and mentors in the NOB that strive every day to make advances in ground-breaking research for brain and spine tumor patients. Read more >

Nanoparticles in the brain

FDA Grants Orphan Drug Designation to Zotiraciclib for the Treatment of Glioma

January 9, 2020

Dr. Jing Wu's investigational drug, zotiraciclib, received orphan drug approval by the FDA for the treatment of glioma, which comprises up to 30% of all brain and central nervous system tumors. Read more >